The inherent limitations of the standard transrectal ultrasound approach for prostate biopsy have led to both diagnostic and therapeutic dilemmas.
Study links PARP inhibitors to increased risk of hematologic toxicity in mCRPC patients
A recently published study found an association between PARP inhibitor treatment and an increased risk of hematological adverse events, including anemia, thrombocytopenia, and neutropenia, in patients with metastatic castration-resistant prostate cancer.
How APPs can bridge the gap in urologist shortages
In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.
Ambient clinical documentation shows promise for physicians
Technology may save health care professionals’ time and help reduce burnout.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Dr. Mian on emerging molecular biomarkers for genitourinary cancers
On an episode of Cleveland Clinic’s Cancer Advances podcast, host Dale Shepard, MD, PhD, talks with Omar Mian, MD, PhD, about emerging molecular biomarkers for genitourinary cancers.
Bone scans overstage prostate cancer vs PSMA-PET in initial setting
"Rather than receiving definitive radiation treatment for localized disease, these patients may have received treatment aimed at preventing the further spread of what was incorrectly identified as metastatic disease," says Thomas Hope, MD.
2 Clarke Drive Cranbury, NJ 08512